CN Bio logoCN Bio logoCN Bio logoCN Bio logo
  • Products
    • Explore our solutions


      PhysioMimix™ products enable you to recreate complex human biology and accurately predict human drug responses

      PhysioMimix OOC

      PhysioMimix OOC systems
      Learn more

      Consumables

      • Multi-chip plates
      • 3D validated cells
      • NASH-in-a-box
      Learn more

      Models

      • Single-organ models
      • Multi-organ models

      Support packages

      • PhysioMimix™ support packages
  • Applications
    • Discover the applications


      Investigate the application areas that our PhysioMimix™ products and services support

      Learn more

      Disease modeling

      • Non-Alcoholic Steatohepatitis
      • Hepatitis B
      • Oncology
      • COVID-19
      Learn more

      Safety toxicology

      • Drug-induced liver injury
      • Immune-mediated toxicities
      Learn more

      ADME

      • Drug absorption
      • Drug metabolism
      • Drug bioavailability
      Learn more
  • Services
    • Studies as a service


      Our team will work collaboratively with you to design a study around your research goals and generate actionable data within weeks

      Learn more
      NAFLD / NASH icons

      NAFLD / NASH

      Drug-induced liver injury icon

      Drug-induced liver injury

      icon adme |

      ADME

      Oncology icon

      Oncology

  • Resources
  • Company
    • About us


      Meet the team, explore our culture and discover what to expect when working with us

      CN Bio team photo
      About us

      Latest news

      • The FDA further expands collaboration with CN Bio to evaluate the PhysioMimix Multi-organ microphysiological system

      • The U.S. FDA Modernization Act 2.0. Now the animal testing mandate is removed, learn what can be embraced in its place.

      • CN Bio appoints Dr Paul Brooks as Chief Executive Officer

      View all news

      Upcoming Events

      • SLAS2023

      • SOT 2023

      • WORD 2023

      • SLAS Europe 2023

      • MPS World Summit 2023

      View all events

      Join the team!

      View all jobs
  • Contact
  • Products
    • PhysioMimix™ OOC Microphysiological Systems
    • Consumables
      • PhysioMimix™ multi-chip plates
      • 3D validated cells
      • NASH-in-a-box
    • Organ-on-a-chip models
    • Support packages
  • Applications
    • Disease modeling
    • Safety toxicology
    • ADME
  • Services
    • Non-Alcoholic Steatohepatitis
    • Drug-Induced Liver Injury
    • ADME
  • Resources
  • Company
    • About us
    • Events
    • News
    • Careers
  • Contact
  • Skip to main content
  • Skip to footer
Chat live with an expert

Organ-on-a-Chip Resources

Resource type

Area of interest

Blogs

Resource image

Pharmacokinetics in mice… or a microfluidic device!

Are you still using xenograft models? Looking for more translatable results? Discover how our oncology services can help you today.

 

Scientific publications

Resource image

A microfluidic system that replicates pharmacokinetic (PK) profiles in vitro improves prediction of in vivo efficacy in preclinical models

Singh et al., 2022

This publication demonstrates the Microformulators capability to incorporate replicated PK exposures into cellular assays to improve in vitro–in vivo translation understanding. This is demonstrated through comparisons to traditional fixed dose in vitro studies and in vivo xenograft models.

Posters

Resource image

Bridging Gaps in Translational Biology

Petreus et al

Developing effective oncology therapies involves defining the right schedules to minimize side effects and maximise efficacy. This requires an accurate understanding of the pharmacokinetic/pharmacodynamics PK/PD relationship of the compound(s). Animal and human PKs can differ significantly and many failures of novel therapies are due to a missing physiologically relevant link between preclinical and clinical data.​

Scientific publications

Resource image

β2-spectrin (SPTBN1) as a therapeutic target for diet-induced liver disease and preventing cancer development

Rao et al., 2021

This study shows the effect of the presence of β2-spectrin (SPTBN1) in the promotion of sterol regulatory element (SRE)–binding protein (SREBP)–stimulated lipogenesis. These findings suggest SPTBN1 could be a potential target for a therapeutic against NASH and liver cancer.

Application notes

Resource image

Pharmacokinetic profiles revisited in 3D microfluidic tumour models

Petreus et al

The efficacy or toxicity of a drug is dependent on the concentration at the target. Current preclinical models mainly rely on in vivo animal studies which often lack translatability to the human. Here, we demonstrate the potential of a new in vitro MPS approach to better predict human PK and improve in vitro to in vivo translational relevance.

Blogs

Resource image

Changing Times, Why Pharmacokinetics Matter in Drug Discovery

Ready to unlock new human-relevant information through our new Oncology Service? This blog discusses all the challenges in drug discovery today and why our Oncology Services could be the missing tool in your toolbox.

Webinars

Resource image

Bringing Life to PK Profiles: In Vivo-Relevance From an In Vitro Environment.

Webinar Series 3 Episode 4:

In this webinar, we introduce a new MPS platform designed to address these challenges: the PhysioMimix™ PK – a novel microformulator developed by CN Bio

Scientific publications

Resource image

IP-10 (CXCL10) Can Trigger Emergence of Dormant Breast Cancer Cells in a Metastatic Liver Microenvironment

Clark et al., 2021

This study elucidated using our MPS platform that CXCR3 ligands were elevated in growing populations of metastatic cancer cells while remaining at physiological levels in the dormant cancer cell site. Upon stimulation with IP-10, dormant cancer cells resulted in a dose-dependent emergence with the metastatic environment playing a significant role.

Webinars

Resource image

A Microphysiological Model of Metastatic Progression

Using systems to model metastatic progression

In this webinar, Dr Amanda Clark, University of Pittsburgh, discusses how to use a Liver MPS to model metastatic progression, evaluate therapeutics and improve our understanding of the bidirectional crosstalk that occurs between host tissue cells and metastatic cancer cells.

Posters

Resource image

Investigating the PK/PD/efficacy relationship of PI3K inhibitors in vitro, enabled by a microfluidic addition and removal device

Singh et al

Characterizing the relationship between pharmacokinetics (PK), pharmacodynamics (PD), and efficacy is critical in the discovery and development of new drugs, schedules, and combinations. This study explores an in vitro methodology using a device capable of recapitulating in vivo PK-like profiles in vitro.

Posters

Resource image

In vitro assessment of combination dosing regimen with in vivo-like pharmacokinetic concentration profiles enabled by a microfluidic addition and removal device

Golby et al

The pharmacokinetic (PK) profile is a determining factor in both the safety and efficacy of a drug or therapeutic regimen. PK profiles can vary significantly between patients and between humans and pre-clinical animal species.​

Here we describe a device capable of recapitulating PK-like profiles in vitro and explore the effects of PK on the treatment of non-small-cell lung carcinoma in mono and combination therapy.

Speak to our experts

Speak directly with one of our OOC experts to see how our products and services can support your studies

Request a meeting

Footer

CN Bio logo

332 Cambridge Science Park, Milton Road
Cambridge, CB4 0WN

+44 (0) 1223 737941

Privacy | Cookies | Terms | Regulatory | Accessibility

©2023 CN Bio Innovations Ltd
Registered No. ‍06517359. VAT No. 978184563

Latest news

  • The FDA further expands collaboration with CN Bio to evaluate the PhysioMimix Multi-organ microphysiological system January 17, 2023
  • The U.S. FDA Modernization Act 2.0. Now the animal testing mandate is removed, learn what can be embraced in its place. January 9, 2023
  • CN Bio appoints Dr Paul Brooks as Chief Executive Officer December 19, 2022

Upcoming events

MPS World Summit 2023 June 26-30, 2023

SLAS Europe 2023 May 22-26, 2023

SLAS2023 February 25 - March 1, 2023